Curevac has been granted a patent for a vaccine that uses mRNA to stimulate a protective anti-influenza immune response in elderly patients. The method involves administering RNA molecules encoding HA antigens from multiple influenza strains, resulting in an enhanced immune response compared to traditional vaccines. GlobalData’s report on Curevac gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Curevac, Personalized cancer vaccines was a key innovation area identified from patents. Curevac's grant share as of May 2024 was 37%. Grant share is based on the ratio of number of grants to total number of patents.
Vaccine for stimulating protective anti-influenza immune response
A recently granted patent (Publication Number: US11975064B2) discloses a method for stimulating a protective anti-influenza immune response in patients by administering a composition containing at least two RNA molecules encoding influenza haemagglutinin (HA) antigens from four different strains of influenza. The RNA molecules have an elevated G/C content in the coding sequence, leading to an enhanced T cell-mediated immune response, specifically a CD8+ T cell-mediated immune response, compared to traditional inactivated influenza vaccines. The method involves intradermal or intramuscular injection of the composition, which may also include RNA encoding additional influenza antigens like neuraminidase, matrix protein, or nucleoprotein.
Furthermore, the patent claims cover various aspects of the method, including the specific subtypes of HA antigens, the structure of the RNA molecules (mRNA with a 5' cap structure and poly-A sequence), and the administration of the composition multiple times. The patent also highlights the use of vehicle, transfection, or complexation agents to increase the transfection efficiency of the mRNA molecules, with examples such as cationic or polycationic compounds, lipid particles, or protamine. Additionally, the patent mentions the substitution of nucleotides with analogs of naturally occurring nucleotides, such as backbone modifications, sugar modifications, or base modifications, to enhance the immune response.
To know more about GlobalData’s detailed insights on Curevac, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
